Department of Surgery, Taichung Veterans General Hospital, 1650 Taiwan Boulevard Sect. 4, Taichung, 40705, Taiwan, ROC.
School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
BMC Gastroenterol. 2023 Mar 8;23(1):56. doi: 10.1186/s12876-023-02691-w.
Bowel gangrene represents a major fatal event in acute mesenteric ischemia. Intestinal resection is inevitable in patients with peritonitis and bowel gangrene. This retrospective study aimed to elucidate the benefit of postoperative parenteral anticoagulation in patients with intestinal resection.
Patients with acute mesenteric ischemia and bowel gangrene were recruited retrospectively between January 2007 and December 2019. All patients underwent bowel resection. They were categorized into two groups: patients without immediate parenteral anticoagulant therapy (Group A) and those with immediate parenteral anticoagulant therapy (Group B). Thirty-day mortality and survival were analyzed.
A total of 85 patients were included, with 29 patients in Group A and 56 patients in Group B. Patients in Group B had lower 30-day mortality (16.1%) and a higher 2-year survival rate (45.4%) than patients in Group A (30-day mortality: 51.7%, p = 0.001; 2-year survival rate: 19.0%, p = 0.001). In the 30-day mortality multivariate analysis, patients in Group B had a better outcome (odds ratio = 0.080, 95% confidence interval between 0.011 and 0.605, p = 0.014). Patients in Group B also had a better outcome in the survival multivariate analysis (hazard ratio: 0.435, 95% confidence interval between 0.213 and 0.887, p = 0.022).
Immediate postoperative parenteral anticoagulant therapy improves prognosis in patients with acute mesenteric ischemia treated by intestinal resection. Trial registration This research was retrospectively approved by the Institutional Review Board (IRB) I&II of Taichung Veterans General Hospital (TCVGH-IRB No.CE21256B) on July 28th, 2021. The informed consent waiver was also approved by IRB I&II of Taichung Veterans General Hospital. The Declaration of Helsinki and ICH-GCP guidelines were followed during this study.
肠坏疽是急性肠系膜缺血的主要致死事件。腹膜炎和肠坏疽患者不可避免地需要进行肠切除术。本回顾性研究旨在阐明肠切除术后术后肠外抗凝的益处。
2007 年 1 月至 2019 年 12 月间回顾性招募急性肠系膜缺血伴肠坏疽患者。所有患者均接受肠切除术。他们分为两组:无即时肠外抗凝治疗组(A 组)和即时肠外抗凝治疗组(B 组)。分析 30 天死亡率和存活率。
共纳入 85 例患者,A 组 29 例,B 组 56 例。B 组患者 30 天死亡率(16.1%)较低,2 年生存率(45.4%)较高,高于 A 组(30 天死亡率:51.7%,p=0.001;2 年生存率:19.0%,p=0.001)。在 30 天死亡率的多变量分析中,B 组患者的预后较好(优势比=0.080,95%置信区间 0.011 至 0.605,p=0.014)。B 组患者的生存多变量分析也有较好的结果(风险比:0.435,95%置信区间 0.213 至 0.887,p=0.022)。
急性肠系膜缺血患者接受肠切除术后立即进行肠外抗凝治疗可改善预后。
本研究于 2021 年 7 月 28 日经台中荣民总医院机构审查委员会(IRB)I&II 批准(TCVGH-IRB 编号 CE21256B)。IRB I&II 还批准了放弃知情同意。本研究遵循赫尔辛基宣言和 ICH-GCP 指南。